Pharmacy Website

Research Grant Opportunities


NIH Notices of Intent

Click here to see all NIH Notices of Intent

 NIH Research Supplement Announcements

 Administrative Supplements to Existing NIH Grants and Cooperative Agreements
PA-12-100

The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted.  Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award.

 

NIH Research Grant Announcements

 
The purpose of this FOA is to encourage Exploratory/Developmental Bioengineering Research Grants (EBRG) applications which establish the feasibility of technologies, techniques or methods that: 1) explore a unique multidisciplinary approach to a biomedical challenge; 2) are high-risk but have a considerable pay-off; and 3) develop data which can lead to significant future research. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.

Announcement #PA-12-284
Posted:  September 11, 2012
Funding Level:
Letter of Intent Due:  NA
Due Date: February 16, June 16, October 16; exp Jan 8, 2016

 

Centers of Excellence for Research on CAM (P01)

This funding opportunity announcement (FOA) is issued by the National Center for Complementary and Alternative Medicine (NCCAM) to enable submission of applications that propose to conduct research that is of high-priority to NCCAM that requires synergistic collaboration between outstanding scientists, and the synthesis of multiple research approaches by multi-disciplinary research teams. The CERC mechanism is designed to support research in which the funding of three or four synergistic, highly meritorious projects as a group offers significant scientific advantages over support of the same projects as individual research grants.  Each CERC must consist, throughout the duration of the award, of three or four research projects, focused on basic, mechanistic, and/or translational research questions relevant to the research priorities described in the current NCCAM Strategic Plan.

Announcement #:PAR-12-151
Posted:  March 30, 2012
Funding Level: $1,250,000 peryear up to 5 years
Letter of Intent Due:  NA
Due Date: September 25,  2013, 2014

NCI Small Grants Program for Cancer Research (NCI Omnibus R03)

This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), of the National Institutes of Health (NIH) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Announcement #:PAR-12-144
Posted:  March 29, 2012
Funding Level: $50,000 per year up to 2 years
Letter of Intent Due:  NA
Due Date: October 16, February 16, June 16; exp. Sept. 8, 2015

Environmental Exposures and Health: Exploration of Non-Traditional Settings, (R01)

The purpose of this funding opportunity announcement (FOA) issued by the National Institute of Nursing Research (NINR) and the National Institute of Environmental Health Sciences (NIEHS) is to encourage interdisciplinary research aimed at promoting health, limiting symptoms and disease, and reducing health disparities in children and older adults living or spending time in non-traditional settings. These settings result in exposure to environmental pollutants and toxins that result in health risks, symptoms, and other health conditions/diseases including lower respiratory diseases, chronic obstructive pulmonary disease, and cardiovascular diseases. Risk identification and symptom management include prevention and behavior changes and actions to maintain health and prevent disease with an emphasis on the individual, family, and community which will advance nursing science. For purposes of this FOA, non-traditional settings, for children and older adults, include, but are not limited to places such as community centers, pre-school and non-traditional school environments (e.g., churches, daycare, home-based schools, dormitories, and alternative schools), child and older adult foster care facilities, older adult day care facilities, half-way homes,  assisted living and long-term care facilities.    

Announcement #:PA-12-133
Posted:  March 23, 2012
Funding Level: $
Letter of Intent Due: NA
Due Date: October 5, February 5; June 5 exp. Sept. 8, 2016

Environmental Exposures and Health: Exploration of Non-Traditional Settings, (R21)

The purpose of this funding opportunity announcement (FOA) issued by the National Institute of Nursing Research (NINR) and the National Institute of Environmental Health Sciences (NIEHS) is to encourage interdisciplinary research aimed at promoting health, limiting symptoms and disease, and reducing health disparities in children and older adults living or spending time in non-traditional settings. These settings result in exposure to environmental pollutants and toxins that result in health risks, symptoms, and other health conditions/diseases including lower respiratory diseases, chronic obstructive pulmonary disease, and cardiovascular diseases. Risk identification and symptom management include prevention and behavior changes and actions to maintain health and prevent disease with an emphasis on the individual, family, and community which will advance nursing science. For purposes of this FOA, non-traditional settings, for children and older adults, include, but are not limited to places such as community centers, pre-school and non-traditional school environments (e.g., churches, daycare, home-based schools, dormitories, and alternative schools), child and older adult foster care facilities, older adult day care facilities, half-way homes,  assisted living and long-term care facilities.      

Announcement #:PA-12-134
Posted:  March 23, 2012
Funding Level: $275,000 over 2 years
Letter of Intent Due:  NA
Due Date: October 16, February 16, June 16; exp. Jan 8, 2016

Translational Research at the Aging/Cancer Interface (TRACI) (R21)

This Funding Opportunity Announcement (FOA) encourages translational research proposals in the overlapping areas of human aging and cancer, linking basic and clinical research relevant to the care of older cancer patients through both bench-to-bedside and bedside-to-bench approaches. Ultimately, information from the research supported by this initiative should improve the health and well-being of elderly patients at risk for, or diagnosed with, cancer and decrease the functional impairment and morbidity associated with cancer in this population. 

Announcement #:PA-12-135
Posted:  March 21, 2012
Funding Level: $275,000 over 2 years
Letter of Intent Due:  NA
Due Date:  October 16, February 16, June 16; exp.May 8, 2015

Translational Research at the Aging/Cancer Interface (TRACI) (R01)

This Funding Opportunity Announcement (FOA) encourages translational research proposals in the overlapping areas of human aging and cancer, linking basic and clinical research relevant to the care of older cancer patients through both bench-to-bedside and bedside-to-bench approaches. Ultimately, information from the research supported by this initiative should improve the health and well-being of elderly patients at risk for, or diagnosed with, cancer and decrease the functional impairment and morbidity associated with cancer in this population. 

Announcement #:PA-12-136
Posted:  March 21, 2012
Funding Level: Not specified up to 5 years
Letter of Intent Due: 
Due Date:  October 5, February 5; exp May 8, 2015

 
Enhancing Cellular Immunity in the Female Reproductive Tract (R01)
 
The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the discovery of mechanisms that mediate the induction and maintenance of effective antigen-specific CD8+ memory T cells in the female reproductive tract (FRT). The ultimate goal is to develop the knowledge base needed to facilitate the development of future vaccines that generate effective and persistent T lymphocyte responses against infection by HIV and other mucosal pathogens in the FRT. This program is not intended to support evaluation of mucosal vaccines or therapies, or research primarily focused on pathogens.

Announcement #:  PA-12-104
Posted:  February 14, 2012
Funding Level: see announcement up to 5 years
Letter of Intent Due:   NA
Due Date:  October 5, February 5, June 5; exp. Jan 8, 2015

NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44)

The purpose of the NHLBI SBIR Phase IIB Bridge Award is to facilitate and accelerate the capital-intensive steps that are required to transition SBIR Phase II projects to the commercialization stage by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners. Applicants must submit a Commercialization Plan, which should include details on any independent third-party funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NHLBI funds being requested throughout the Phase IIB Bridge Award project period. Projects proposed in response to this FOA must relate to the NHLBI mission and require eventual Federal regulatory approval/clearance. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate, but are not required.

Announcement #:RFA-HL-13-016
Posted:  February 17, 2012
Funding Level: $1,000,000 for 3 years
Letter of Intent Due: May 19, 2014
Due Date: June 19,  2014

Senior Scientist Research Award (K05)

The purpose of the Senior Scientist Research (K05) is intended to provide protected time for outstanding senior scientists who have demonstrated a sustained high level of productivity conducting biomedical research relevant to the scientific mission of the appropriate institute to focus on their research and to provide mentoring of new investigators.    

Announcement #:PA-12-048
Posted:  March 30, 2012
Funding Level: $25,00 per year plus 75% salary (capped at $90,000)
Letter of Intent Due:  NA
Due Date: October 12, February 12; exp May 8, 2015

Infrastructure Development Program in Patient-Centered Outcomes Research (PCOR) (R24)

Purpose. This FOA solicits Resource-Related Research Projects (R24) grant applications from organizations that propose to improve health outcomes by developing and disseminating evidence-based information to patients, clinicians, policy makers, and health care administrators, responding to their expressed needs about which clinical and health system design interventions are most effective for which patients under specific circumstances. Mechanism of Support. This FOA will use the AHRQ Resource-Related Research Projects (R24) grant mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the numbers, quality, duration, and costs of the applications received. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Announcement #:PA-12-114 
Posted: February 23, 2012
Funding Level: $250,000 per year up to 3 or 5 years
Letter of Intent Due:  NA
Due Date:   December 19, 2013, December 19, 2014

Minor Use Minor Species Development Drugs

Applications for the smaller grants ($75,000) may be for any safety or effectiveness study supportive of new animal drug approval or conditional approval of the designated product for a designated intended use. Study proposals for the larger grants ($125,000) must be for studies that are of necessity of unusual complexity, duration, or size. FDA grants policies as described in the HHS Grants Policy Statement http://www.hhs.gov/grantsnet/adminis/gpd/index.htm will apply to the applications submitted and awards made in response to this FOA. Facilities and Administrative (F&A) costs requested by consortium participants are not included in the direct cost limitation. See NOT-OD-05-004. 

Announcement #:RFA-FD-12-003
Posted:  February 23, 2012
Funding Level: $75,000 to $125,000 total costs per year up to 3 years.
Letter of Intent Due: 
Due Date:  July 26, 2013, December 6, 2013, July 18, 2014, December 5, 2014; exp. Dec 5, 2014

Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to address
different and complementary research needs for the development and
acceptability of pediatric drug formulations in different age groups.
Development and testing of novel pediatric drug delivery systems is also
part of this initiative.
Investigators are encouraged to explore
approaches and concepts new to the area of pediatric formulation
development and testing and use newly developed techniques superior to
the ones currently used in the field.

Announcement #: PAR-11-303
Posted:  August 11, 2011
Funding Level: $275,000 total up to 2 years
Letter of Intent Due:  30 days before due date
Due Date:  October 16, February 16, June 16; Exp Sept 8, 2014

Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R03)

The purpose of this Funding Opportunity Announcement (FOA) is to address
different and complementary research needs for the development and
acceptability of pediatric drug formulations in different age groups.
This FOA also encourages the development of novel drug delivery systems
in the pediatric population. Investigators are encouraged to explore
approaches and concepts new to the area of pediatric formulation
development, testing and use of newly developed techniques superior to
the ones currently used in the field.

Announcement #: PAR-11-302
Posted:  August 11, 2011
Funding Level: $50,000 total up to 2 years
Letter of Intent Due:   30 days before due date
Due Date:  October 16, February 16, June 16; Exp Sept 8, 2014

Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to address
different and complementary research needs for the development and
acceptability of pediatric drug formulations in different age groups.
Development and testing of novel pediatric drug delivery systems is also
part of this initiative.  Investigators are encouraged to explore
approaches and concepts new to the area of pediatric formulation
development and testing and use newly developed techniques superior to
the ones currently used in the field.

Announcement #: PAR-11-303
Posted:  August 11, 2011
Funding Level: $275,000 total over 2 years
Letter of Intent Due:   30 days before due date
Due Date:  October 16, February 16, June 16; Exp Sept 8, 2014

 
Development of Appropriate Pediatric Formulations and Drug Delivery Systems SBIR (R43)

This Funding Opportunity Announcement (FOA) invites Small Business
Innovation Research (SBIR) grant applications from small business
concerns (SBCs) to address different and complementary research needs
for the development appropriate pediatric drug formulations in different
age groups. This FOA also encourages the development and testing of
novel drug delivery systems in the pediatric population.

The goal
of this FOA is not to duplicate or compete with the private sector but
to complement and accelerate the development of appropriate pediatric
drugs formulations and drug delivery systems.

Announcement #: PAR-11-304
Posted:   August 11, 2011
Funding Level: $150,000 for Phase I.
Letter of Intent Due:  30 days before due date
Due Date:  December 5, August 5, August 5:  Exp Sept 8, 2014

Development of Appropriate Pediatric Formulations and Drug Delivery Systems SBIR (R41)

This Funding Opportunity Announcement (FOA) invites Small Business
Technology Transfer (STTR) grant applications from small business
concerns (SBCs) to address different and complementary research needs
for the development appropriate pediatric drug formulations in different
age groups. This FOA also encourages the development and testing of
novel drug delivery systems in the pediatric population.
The goal of
this FOA is not to duplicate or compete with the private sector but to
complement and accelerate the development of appropriate pediatric drugs
formulations and drug delivery systems.

Announcement #: PAR-11-305
Posted:   August 11, 2011
Funding Level: $100,000 for Phase I, one year.
Letter of Intent Due:  30 days before due date
Due Date:  December 5, August 5, August 5:  Exp Sept 8, 2014

Nanoscience and Nanotechnology in Biology and Medicine (R21)

This initiative, issued by the National Institutes of Health, encourages
applications from institutions/organizations that apply nanoscience and
nanotechnology approaches to address problems in biology and medicine. 
The purpose of this FOA is to provide support for cutting-edge
nanoscience and nanotechnology research that can lead to biomedical
breakthroughs and new investigations into the diagnosis, treatment and
management of an array of diseases and traumatic injuries.  Nanoscience
and nanotechnology have the capacity to drive a new wave of medical
innovation through the engineering of bioactive nanoscale structures,
processes and systems based on the advancement of our understanding of
biology at the nanoscale.  Therefore, this FOA will also support
research projects that develop new or improved nanotechnology and
nanoscience-based tools, methods, concepts, and devices that lead to a
better understanding of basic biology in addition to conducting
translational biomedical studies.  Because this FOA utilizes the R21
grant mechanisms, applications that focus on novel or exploratory
approaches that are risky but have potentially a high impact are
encouraged as well as proposed discovery research that may lead to new
areas of biomedical investigations.

Announcement #: PAR-11-149
Posted:  March 14, 2011
Funding Level:  $275,000 for 2 years; no more than $200,000 in any year
Letter of Intent Due:   NA
Due Date:   October 16, February 16, June 16; Exp May 8, 2014

Pilot studies in Pancreatic Cancer (R21)

This funding opportunity announcement (FOA), issued by the National Cancer
Institute (NCI) of the National Institutes of Health (NIH), encourages
the submission of Research Project Grant (R21) applications from
institutions and organizations that propose to promote innovative
research across multiple disciplines for a better understanding of the
biology, etiology, detection, prevention, and treatment of pancreatic
cancer.
Announcement #: PA-11-297
Posted:  August 9, 2011
Funding Level: $275,000 total for 2 years
Letter of Intent Due:  NA
Due Date:   October 16, February 16, June 16; Exp Jan 8, 2015

Pilot studies in Pancreatic Cancer (R03)

This funding opportunity announcement (FOA), issued by the National Cancer
Institute (NCI) of the National Institutes of Health (NIH), encourages
the submission of Small Research Grant (R03) applications from
institutions and organizations that propose to promote innovative
research across multiple disciplines for a better understanding of the
biology, etiology, detection, prevention, and treatment of pancreatic
cancer. The R03 grant mechanism supports different types of projects
including pilot and feasibility studies; secondary analysis of existing
data; small, self-contained research projects; development of research
methodology; and development of new research technology. The R03 is
intended to support small research projects that can be carried out in a
short period of time with limited resources.

Announcement #: PA-11-298
Posted:  August 9, 2011
Funding Level: $50,000 per year up to 2 years
Letter of Intent Due:  NA
Due Date:   October 16, February 16, June 16; Exp Jan 8, 2015

Molecular and Cellular Substrates of Complex Brain Disorders (R01)

This Funding Opportunity Announcement (FOA) encourages research grant
applications from applicant organizations directed toward the discovery
of the impact of alterations associated with complex brain disorders on
the fundamental cellular and molecular substrates of neuronal function.

Announcement #: PAR-11-299
Posted:  August 10, 2011
Funding Level: Not specified up to 5 years
Letter of Intent Due:  NA
Due Date:  October 5, February 5,  June 5; Exp Sept 8, 2014

Molecular and Cellular Substrates of Complex Brain Disorders (R21)

This Funding Opportunity Announcement (FOA) encourages research grant
applications from applicant organizations directed toward the discovery
of the impact of alterations associated with complex brain disorders on
the fundamental cellular and molecular substrates of neuronal function.

Announcement #: PAR-11-300
Posted:  August 10, 2011
Funding Level: $275,000 total over two years
Letter of Intent Due:  NA
Due Date:  October 16, February 16,  June 16; Exp Sept 8, 2014

 
Solicitation of Assays for High Throughput Screening (HTS) to Discover Chemical Probes (R01)

This
Funding Opportunity Announcement (FOA) encourages investigators to form
collaborations with an established academic, nonprofit, or commercial
high throughput screening (HTS) facility that has the requisite
expertise and experience to implement HTS-ready assays for the discovery
and development of small molecule chemical probes. Through this FOA,
NIH wishes to stimulate research in 1) discovery and development of
novel, small molecules for their potential use in studying disease
treatment relevant to the missions of the participating NIH Institutes,
and 2) discovery and/or validation of novel, biological targets that
will inform studies of disease mechanisms.  Emphasis will be placed on
assays that provide new insight into important disease targets and
processes.

Announcement #: PAR-12-058
Posted:  December 13, 2011
Funding Level:  Not specified up to 3 years
Letter of Intent Due:  30 days prior to application
Due Date:  October 16, February 16,  June 16; Exp Sept 8, 2014

Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes (R01)

This Funding Opportunity Announcement (FOA) intends to support investigators
who have interest and capability to join efforts for the discovery of
in vivo chemical probes. It is expected that applicants will have in
hand the starting compounds (“validated hits”) for chemical optimization
and bioassays for testing new analog compounds. Through this FOA, NIH
wishes to stimulate research in 1) discovery and development of novel,
small molecules for their potential use in studying disease treatment
relevant to the missions of the participating NIH Institutes, and 2)
discovery and/or validation of novel, biological targets that will
inform studies of disease mechanisms.  Emphasis will be placed on assays
that provide new insight into important disease targets and processes.

Announcement #: PAR-12-060
Posted:  December 13, 2011
Funding Level: Not specified up to 3 years
Letter of Intent Due:  30 days prior
Due Date:  February 5, June 5, October 5: Exp Sept 8, 2014

Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities (R21)

Through this Funding Opportunity Announcement (FOA), the Center to Reduce Cancer Health Disparities (CRCHD) and the Division of Cancer Biology (DCB), at the National Cancer Institute (NCI), invite grant applications from investigators interested in conducting basic research studies into the biological causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies, development and testing of new methodologies, secondary data analyses, and innovative mechanistic studies that investigate biological/genetic bases of cancer health disparities. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research and to provide resources for those investigators that may need additional support on their path to successfully compete for R01 funding in basic mechanistic research in understanding cancer health disparities.

Announcement #: PAR-12-094
Posted:  February 2, 2012
Funding Level: $275,000 per year up to two years
Letter of Intent Due:  NA
Due Date:   2013- June 20, November 20; 2014- June 20, November 20; exp. Nov. 21, 2014

Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21)

This funding opportunity announcement (FOA), issued by the Center to Reduce Cancer Health Disparities (CRCHD) and the Division of Cancer Biology (DCB) of the National Cancer Institute (NCI), invites applications by investigators from diverse backgrounds underrepresented in basic and biomedical cancer research. The NIH recognizes a unique and compelling need to promote diversity in the NIH-funded research workforce. The purpose of this FOA is to improve the diversity of the NCI-funded research workforce by supporting and recruiting eligible investigators from groups that have been shown to be underrepresented in the biomedical, clinical, behavioral, and social sciences including individuals from underrepresented racial and ethnic groups, individuals with disabilities, and individuals from socially, culturally, economically, or educationally disadvantaged backgrounds that have recently and demonstrably inhibited their ability to pursue a career in health-related research. This funding opportunity will also provide a bridge to investigators that have completed their research training and may need extra time to develop a research project grant application.

Announcement #:    PAR-12-096
Posted:  February 2 , 2012
Funding Level: $275,000 per year up to two years
Letter of Intent Due:  NA
Due Date:  2013- June 20, November 20; 2014- June 20, November 20; exp. Nov. 21, 2014

New Technologies for Viral Hepatitis STTR (R41/R42)

he purpose of this Funding Opportunity Announcement (FOA) is to encourage Small Business Innovation Research (STTR) grant applications from small business concerns (SBCs) that propose to respond to the Combating the Silent Epidemic of Viral Hepatitis: U.S. Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis (Viral Hepatitis Action Plan) which was released on May 12, 2011 (http://www.hhs.gov/ash/initiatives/hepatitis/).  SBCs are encouraged to propose STTR grant applications to develop resources, research tools, instrumentations, biomarkers, devices, drugs or new and innovative approaches to diagnosis, monitoring, management, treatment and prevention of viral hepatitis and viral hepatitis associated liver disease.

Announcement #:PA-12-091
Posted:  January 31, 2012
Funding Level: $150,000 Phase I for 6 months
Letter of Intent Due:  NA
Due Date: August 5, December 5, April 5; exp. Jan 8, 2015

New Technologies for Viral Hepatitis SBIR (R43/R44)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to respond to the Combating the Silent Epidemic of Viral Hepatitis: U.S. Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis (Viral Hepatitis Action Plan) which was released on May 12, 2011 (http://www.hhs.gov/ash/initiatives/hepatitis/).  SBCs are encouraged to propose SBIR grant applications to develop resources, research tools, instrumentations, biomarkers, devices, drugs or new and innovative approaches to diagnosis, monitoring, management, treatment and prevention of viral hepatitis and viral hepatitis associated liver disease.   
 
Announcement #:PA-12-090
Posted:  January 31, 2012
Funding Level: $150,000 Phase I for 6 months
Letter of Intent Due:  NA
Due Date:  July 16, November 16, March 16; exp. Jan 8, 2015

Network and Infrastructure Support for Development of Interdisciplinary Aging Research (R24)

The purpose of this FOA is to provide network and infrastructure support to foster development of novel interdisciplinary research approaches on important topics in aging research. This FOA will use the NIH Resource-Related Research Project (R24) mechanism to facilitate research networks that will advance specific scientific goals through activities such as meetings, conferences, small scale pilots, short term training opportunities, and visiting scholar programs, and dissemination activities to encourage growth and development in these interdisciplinary areas.

Announcement #: PA-12-064
Posted:  December 21, 2011
Funding Level: $see announcement up to 5 years
Letter of Intent Due:  NA
Due Date:  May 25, September 25, 2012; exp. Jan 8, 2015

Imaging - Science Track Award for Research Transition (I/START) [R03]

This funding opportunity announcement (FOA) issued by the National Institute on Drug Abuse encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources.

Announcement #: PAR-12-066 Posted:  
Funding Level: $150,000 per year for one year only
Letter of Intent Due:  30 days before due date
Due Date:  June 16, October 16; exp. Jan 8, 2015

 Role of Environmental Chemical Exposures in the Development of Obesity, Type 2 Diabetes and Metabolic Syndrome (R01) (R21)

The Funding Opportunity Announcement, issued by the National Institute of Environmental Health Sciences (NIEHS), encourages grant applications to understand the role of environmental chemical exposures in the development of obesity, type 2 diabetes and/or metabolic syndrome. Applications must link an environmental exposure to the increased incidence of weight gain, glucose tolerance/insulin sensitivity and aspects of metabolic syndrome in animal models or human studies. While any exposure window is acceptable it is anticipated that the most sensitive time for exposures to affect the disease outcomes will be during development e.g. in utero and/or neonatal or early childhood. For human studies developmental exposures (in utero and early childhood) should be linked to early biomarkers of disease onset. Animal studies should focus on identifying environmental chemicals that alter endpoints indicative of affecting disease development and the site and mechanism(s) of the effects that lead to the increased disease incidence.

Announcement #:  PA-12-185 (R01) PA-12-184  
Posted:      May 11, 2012
Funding Level:
Letter of Intent due: NA
Due Date: October 5, February 5, June 5; exp. Sept 8 2015

NHLBI Systems Biology Collaborations (R01)

This FOA issued by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, encourages Research Project Grant (R01) applications from institutions/organizations that propose collaborative systems biology research projects by multi-disciplinary teams to advance our understanding of normal physiology and perturbations associated with heart, lung, blood, and sleep (HLBS) diseases and disorders. Multi-disciplinary expertise across experimental and computational domains is required, and the multi-PI mechanism is allowed, as integration across these domains is a critical element of the proposed research plan.

Announcement #: PAR-12-138
Posted:  March 23, 2012
Funding Level: Not specified, up to 5 years
Letter of Intent Due:  August 14, 2012; December 14, 2012; August 13, 2013; December 13, 2013; August 15, 2014; December 13, 2014
Due Date:  J September 13, 2013; January 13, 2014; September 15, 2014; January 13, 2015 (exp. Jan 14, 2015)

NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21)

The National Cancer Institute (NCI) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in all areas of cancer research. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).

Announcement #:PAR-12-145
Posted:  March 29, 2012
Funding Level: $275,000 for 2 years
Letter of Intent Due:  NA
Due Date:  June 16, October 16, February 16; exp. Sept. 8, 2015

NCI Small Grants Program for Cancer Research (NCI Omnibus R03)

This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI), of the National Institutes of Health (NIH) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Announcement #:PAR-12-144
Posted:  March 29, 2012
Funding Level: $50,000 per year up to 2 years
Letter of Intent Due:  NA
Due Date:  June 16, October 16, February 16; exp. Sept. 8, 2015

Translational Research at the Aging/Cancer Interface (TRACI) (R21)

This Funding Opportunity Announcement (FOA) encourages translational research proposals in the overlapping areas of human aging and cancer, linking basic and clinical research relevant to the care of older cancer patients through both bench-to-bedside and bedside-to-bench approaches. Ultimately, information from the research supported by this initiative should improve the health and well-being of elderly patients at risk for, or diagnosed with, cancer and decrease the functional impairment and morbidity associated with cancer in this population. 

Announcement #: PA-12-135
Posted:  March 21, 2012
Funding Level: $275,000 for 2 years
Letter of Intent Due:  NA
Due Date:  June 16, October 16, February 16; exp May 8, 2015

Translational Research at the Aging/Cancer Interface (TRACI) (R21)

This Funding Opportunity Announcement (FOA) encourages translational research proposals in the overlapping areas of human aging and cancer, linking basic and clinical research relevant to the care of older cancer patients through both bench-to-bedside and bedside-to-bench approaches. Ultimately, information from the research supported by this initiative should improve the health and well-being of elderly patients at risk for, or diagnosed with, cancer and decrease the functional impairment and morbidity associated with cancer in this population. 

Announcement #: PA-12-136
Posted:  March 21, 2012
Funding Level:  Not specified up to 5 years
Letter of Intent Due:  NA
Due Date:  June 5, October 5, February 5; exp May 8, 2015

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21)

This Funding Opportunity Announcement (FOA), issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the Office of Dietary Supplements (ODS) encourages R21 applications that propose to conduct secondary analysis of existing data sets relevant to diabetes and endocrine and metabolic diseases; digestive diseases and nutrition, including obesity and eating disorders; and kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets.

Announcement #: PA-12-125
Posted:  March 19, 2012
Funding Level: $275,000 over 2 years
Letter of Intent Due:  NA
Due Date:  June 5, October 5, February 5; exp May 8, 2015

 Patient Safety Research during Neonatal Care (R03)

This FOA encourages a wide range of collaborative research projects related
to patient safety in the context of both routine as well as intensive
newborn care. The FOA welcomes proposals related to (but not limited
to): the epidemiology of various domains of medical errors and
consequent patient harm; assessing the factors at various levels that
contribute to such errors; and intervention strategies at individual,
systems, and institutional-levels to help reduce and eliminate medical
errors in the context neonatal care. It is anticipated that knowledge
gained from these projects will help develop strategies to deliver
highest quality of healthcare to all newborn infants with utmost safety
and effectiveness.

Announcement #: PAR-11-226
Posted:  June 9, 2011
Funding Level: $100,000 total for two years
Letter of Intent Due:  August 19, 2011, August 19, 2012, August 19, 2013
Due Date:    September 19, 2013

Patient Safety Research During Neonatal Care (R01)

This FOA encourages a wide range of collaborative research projects related
to patient safety in the context of both routine as well as intensive
newborn care. The FOA welcomes proposals related to (but not limited
to): the epidemiology of various domains of medical errors and
consequent patient harm; assessing the factors at various levels that
contribute to such errors; and intervention strategies at individual,
systems, and institutional-levels to help reduce and eliminate medical
errors in the context neonatal care. It is anticipated that knowledge
gained from these projects will help develop strategies to deliver
highest quality of healthcare to all newborn infants with utmost safety
and effectiveness.

Announcement #: PAR-11-225
Posted:  June 9, 2011
Funding Level: $100,000 total for two years
Letter of Intent Due:  August 19, 2011, August 19, 2012, August 19, 2013
Due Date:  September 19, 2013

Patient Safety Research During Neonatal Care (R21)

This FOA encourages a wide range of collaborative research projects related
to patient safety in the context of both routine as well as intensive
newborn care. The FOA welcomes proposals related to (but not limited
to): the epidemiology of various domains of medical errors and
consequent patient harm; assessing the factors at various levels that
contribute to such errors; and intervention strategies at individual,
systems, and institutional-levels to help reduce and eliminate medical
errors in the context neonatal care. It is anticipated that knowledge
gained from these projects will help develop strategies to deliver
highest quality of healthcare to all newborn infants with utmost safety
and effectiveness.

Announcement #: PAR-11-227
Posted:  June 9, 2011
Funding Level: $100,000 total for two years
Letter of Intent Due:  August 19, 2011, August 19, 2012, August 19, 2013
Due Date:  September 19, 2013

 

T1 Translational Research:  Novel interventions for prevention and treatment of age-related conditions (R21)


This funding opportunity announcement (FOA) encourages
exploratory/developmental R21 research projects to accelerate the pace
of development of novel therapeutics involving biologics,
pharmacological and non-pharmacological approaches for preventing and
treating key health issues affecting the elderly.   For the purposes of
this FOA, T1 translational research on aging is defined as the
application of basic and clinical biomedical findings towards the
development of new strategies for prevention and treatment of
age-related pathologies. For projects proposing basic research that is
being conducted in animal models, the potential to treat a clinical
age-related pathology must be clearly stated in the proposal.  Direct
relevance of the data to a clinical aging condition must be established
and clearly stated in the application.
Announcement #: PAS-11-280
Posted:  July 25, 2011
Funding Level:  $275,000 over 2 years
Letter of Intent Due:  NA
Due Date:  October 16, February 16, June 16; exp Sept 8, 2014

Planning Grants for Clinical Trials of High Relevance to the NIGMS Mission (R34)

The purpose of this funding opportunity announcement is to permit early
peer review of the scientific rationale for a proposed clinical trial,
and to facilitate the complete submission of a subsequent research grant
application to support the full scale clinical trial.  The R34 planning
grant mechanism is intended to provide time and support for an
applicant to prepare, organize, and make oversight arrangements prior to
consideration of an investigator-initiated application for a full
clinical trial.  Activities supported by a planning grant could include
development of a Manual of Procedures, creation of a Data Safety and
Monitoring Board charter, development of data handling and statistical
analysis plans, establishment of recruitment sites, preparation of
preliminary submissions for regulatory approvals, development of
training materials, and other tasks essential to a trial.  Following
funding and successful completion of a planning grant, a clinical trial
that is highly relevant to the institute's mission may be submitted to
NIGMS as an R01 grant application.
Announcement #: PAR-11-287
Posted:  August 1, 2011
Funding Level:
Letter of Intent Due:  September 24, 2013
Due Date:   October 24, 2013

Collaborative Interdisciplinary Team Science in NIDDK Research Areas (R24)

Collaborative
Interdisciplinary Team Science Awards will foster the application of
interdisciplinary, integrative and/or paradigm-shifting approaches to
address complex challenges in biomedical research relevant to the
National Institute of Diabetes and Digestive and Kidney Diseases.  The
NIDDK supported R24 grant mechanism is designed to apply the flexibility
of the Research Resource Project Grant mechanism (R24) to accommodate
many forms of approaches including discovery-based or
resource-generating and hypothesis-driven or hypothesis-generating
science.

Announcement #: PAR-11-221
Posted:  June 2, 2011
Funding Level:  $500,000 annual up to five years
Letter of Intent Due:  NA
Due Date:   November 15, 2013

 

 HIV/AIDS

Functional Glycomics in HIV Vaccine Design (R01)

Glycans play key roles in the transmission, antigenicity, and immunogenicity of
the HIV-1 envelope protein. Glycans also modulate the immune response,
playing an essential role in both innate and adaptive immunity. The
purpose of this Funding Opportunity Announcement (FOA)  is to stimulate
and foster multi-disciplinary investigator- initiated collaborative
research to 1) investigate structural and conformational features of
glycosylation that may lead to novel HIV vaccine design approaches, and
2) to elucidate the impact of differential glycosylation on the quality
of the immune response to HIV. Ultimately, the discovery of a safe,
effective, prophylactic vaccine that provides long-term protection from
HIV infection may depend on novel approaches that incorporate new
knowledge of the key role glycans play in the elicitation and maturation
of broadly neutralizing antibodies and effector immune responses. 

Announcement #:  PA-12-105
Posted:  February 14, 2012
Funding Level: see announcement up to 5 years
Letter of Intent Due:   NA
Due Date:  February 5, June 5, October 5; exp. Jan 8, 2015

 
Delivering Therapeutics to Residual Active HIV Reservoirs (R01)

The purpose of this Funding Opportunity Announcement is to encourage new
ideas for eliminating cellular reservoirs of HIV that continue to
actively produce virus in tissue compartments despite suppression of
plasma viremia with antiretroviral therapy. New approaches to delivering
antiretrovirals or other anti-HIV agents to these tissues or to
specific cell types are needed to block virus production, limit
inflammation, and facilitate clearance of these reservoir cells.

Announcement #:  PA-12-107
Posting Date:  February 15, 2012
Funding Level:
Letter of Intent: NA
Due Date:  June 5, October 5, February 5; exp. Jan. 8, 2015

 
 
Targeting Persistent HIV Reservoirs (TaPHIR) (R21/R33)

The purpose of this FOA is to stimulate the development of innovative tools and strategies for curing HIV infection. HIV establishes latent infection in long-lived cells that form a reservoir of virus that persists in infected individuals even after years of treatment with highly active antiretroviral therapy (HAART). Curing HIV infection requires innovative strategies to identify and eliminate these reservoir cells. The task is especially difficult given the lack of HIV protein expression during latency and the low frequency of latently infected cells during treatment. Novel approaches are therefore sought to efficiently monitor and specifically target reservoirs of latently infected cells to facilitate the testing of strategies to cure HIV infection in vivo.  

Announcement #:  PAR-12-109
Posted:  Fevruary 17, 2012
Funding Level:
Letter of Intent Due: March 25, 2012, 2013, 2014
Due Date:  April 25,  2014
 
Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R01)

The Division of AIDS Research (DAR) at the National Institute of Mental
Health (NIMH) issues this Funding Opportunity Announcement (FOA) to
outline priority areas for innovative intervention development research
to advance HIV prevention and care. This FOA encourages research
designed to (a) conduct tests of the efficacy of novel behavioral and/or
integrated behavioral and biomedical interventions, (b) conduct basic
behavioral and social science research that is needed to advance the
development of innovative interventions, and (c) translate and
operationalize the findings from these basic studies to develop
interventions and assess their feasibility. This FOA is informed by
priority areas from the National HIV/AIDS Strategy, the NIH Office of
AIDS Research (OAR) Plan for HIV/AIDS Related Research, as well as the
NIMH Strategic Plan 
http://www.nimh.nih.gov/about/strategic-planning-reports/index.shtml,
particularly objectives 1, 2, and 3 as adapted to HIV research.
This
FOA encourages novel, high impact research approaches that will
contribute to the creation of empirically-based HIV-risk reduction
approaches that could be used to pave the way for prevention, reduction
of clinical impact, and cure. High impact can be achieved either by
large effect size or very broad reach.  To achieve these goals, this FOA
outlines the need to: (1) advance combination behavioral-biomedical
approaches to HIV-related interventions, (2) increase intervention
potency and durability, (3) enhance targeting on high risk vulnerable
populations, (4) identify new behavioral targets and intervention
approaches within multiple intervention areas (e.g., to serve novel HIV
prevention and treatment adherence interventions), and (5) incorporate
context into intervention development and testing, thereby advancing the
development and testing of interventions delivered beyond the
individual level.

Announcement #: PA-11-275
Posted:  July 26, 2011
Funding Level: Not specified up to 5 years
Letter of Intent Due:  NA
Due Date:  February 5, June 5, October 5; exp May 8, 2014

 

Mucosal Environment and HIV Prevention (MEHP) (R01)

The
National Institute of Allergy and Infectious Diseases (NIAID), National
Institutes of Health, encourages grant applications from
institutions/organizations that address the long term goal and
objectives of increasing the safety and efficacy of non-vaccine
biomedical prevention, such as microbicides and PrEP, through a better
understanding of their interactions with the tissue micro- and
macro-environments of the genital (male and female) and gastrointestinal
mucosa.

Announcement #:  PA-12-106
Posted:  February 14, 2012
Funding Level: see announcement up to 5 years
Letter of Intent Due:   NA
Due Date:  February 5, June 5, October 5; exp. Jan 8, 2015

Basic Research on HIV Persistence (R01) (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to increase our understanding of persistent HIV-1 infection in patients under highly active anti-retroviral therapy (HAART). Support would be through soliciting Research Project Grant (R01) applications for hypothesis-driven basic research in HIV/AIDS that is focused on directly achieving this aim. The emphasis of this initiative is on the development of new ideas and approaches in HIV-1 persistence including model and assay development that may directly inform future studies on the design of therapeutic strategies to achieve long term remission without treatment or a complete eradication of residual virus and complete cure for HIV infection and AIDS.

Announcement #: PA-12-161 (R01) and PA-12-162 (R21)
Posted:  April 12, 2012
Funding Level:  Not specified up to 5 years (R01) and $275,000 for 2 years (R21)
Letter of Intent Due:   NA
Due Date:  June 5, October 5, February 5; exp. Jan 8, 2015

 


NSF Grant Announcements

Click here for a list of all open NSF opportunities
Click here for all  NSF opportunities  in Biology
Click here for all  NSF opportunities  in Cross-Cutting Issues
Click here for all NSF opportunites in Education
Click here for all  NSF opportunities  in Integrated Activities
Click here for all  NSF opportunities  in Social, Behavioral, Economic Research

Grant Opportunities for Academic Liaison with Industry (GOALI)

Grant
Opportunities for Academic Liaison with Industry (GOALI) promotes
university-industry partnerships by making project funds or
fellowships/traineeships available to support an eclectic mix of
industry-university linkages. Special interest is focused on affording
the opportunity for:

    Faculty, postdoctoral fellows, and students to conduct research and gain experience in an industrial setting;
    Industrial scientists and engineers to bring industry's perspective and integrative skills to academe; and
    Interdisciplinary university-industry teams to conduct research projects.

This
solicitation targets high-risk/high-gain research with a focus on
fundamental research, new approaches to solving generic problems,
development of innovative collaborative industry-university educational
programs, and direct transfer of new knowledge between academe and
industry. GOALI seeks to fund transformative research that lies beyond
that which industry would normally fund.
Announcement #:  SF 10-580
Posted:  November 17, 2011
Funding Level: Approx. $50,000
Letter of Intent Due: NA
Due Date: contacct program office to obtain deadlines

Research Coordination Networks (RCN)

The goal of the RCN program is to advance a field or create new directions
in research or education. Groups of investigators will be supported to
communicate and coordinate their research, training and educational
activities across disciplinary, organizational, geographic and
international boundaries. RCN provides opportunities to foster new
collaborations, including international partnerships, and address
interdisciplinary topics. Innovative ideas for implementing novel
networking strategies, collaborative technologies, and development of
community standards for data and meta-data are especially encouraged.

Announcement #: NSF 11-531
Posted:  April 8, 2011
Funding Level:  $50,000 to $750,000
Letter of Intent Due:  NA
Due Date: See announcement

Grant Opportunities for Academic Liaison with Industry

 (GOALI)

Grant Opportunities for Academic Liaison with Industry (GOALI) promotes
university-industry partnerships by making project funds or
fellowships/traineeships available to support an eclectic mix of
industry-university linkages. 

Announcement #: NSF 12-513
Funding Level:  See announcement
Letter of Intent Due:  NA
Due Date: See announcement

 International Collaboration in Chemistry between US Investigators and their Counterparts Abroad

 (ICC) 

 The National Science Foundation (NSF) seeks to enhance opportunities for
collaborative activities between U.S. and foreign investigators. To
realize this goal, the Division of Chemistry at NSF has partnered with
the Fonds zur Förderung der wissenschaftlichen Forschung (FWF; Austrian
Science Fund) of Austria, the Agence Nationale de la Recherche (ANR;
National Research Agency) of France, the Fundacao de Amparo a Pesquisa
do Estado de Sao Paulo (Sao Paulo Research Foundation) of Brazil
(FAPESP), Japan Society for the Promotion of Science (JSPS), the Fonds
National de la Recherche (FNR; National Research Fund) of Luxembourg,
the Russian Foundation for Basic Research (RFBR), Spain Ministerio de
Ciencia e Innovacion (MICINN; Ministry of Science and Innovation), the
National Science Council of Taiwan (NSC), and the Engineering and
Physical Sciences Research Council (EPSRC) of the United Kingdom.
Announcement #: NSF 11-585
Funding Level:  See announcement
Letter of Intent Due:  NA
Due Date: See announcement


 

 Other Federal Grant Announcements

Click here to see all open EPA grant opportunities

 

 Click here to see CDMRP opportunites with DoD